Health and economic impact of geographically prioritized long-acting PrEP delivery in southern and eastern Africa

This study demonstrates that geographically prioritizing the delivery of long-acting injectable PrEP (Lenacapavir) to high-incidence districts in southern and eastern Africa significantly enhances its cost-effectiveness and impact, enabling efficient HIV prevention with limited resources by targeting specific demographic groups where incidence is highest.

The Gist

Imagine you are the captain of a massive ship trying to put out fires on a continent. The "fire" is HIV, and the "water" is a new, powerful medicine called Lenacapavir. This medicine is special because it's a long-acting injection (like a shield that lasts six months) that stops people from catching the virus.

However, there's a problem: The ship's water tank is small (limited budget), and the water is expensive. You can't spray water everywhere at once. If you spray it on a damp patch of grass where no fire is burning, you waste precious water. If you spray it on a raging inferno, you save lives.

This paper is essentially a map and a strategy guide for the captain. It asks: "Where should we aim our water hose to put out the most fires for the least amount of money?"

Here is the breakdown of their findings using simple analogies:

1. The "Fire Map" (Geography Matters)

The researchers looked at 837 different towns (districts) across 11 countries in Southern and Eastern Africa. They found that the "fires" (new HIV infections) aren't spread out evenly like a light mist. Instead, they are like wildfires concentrated in specific patches.

• The Finding: 50% of all new infections happen in areas that only contain 20% of the people.
• The Analogy: Imagine a forest where 80% of the trees are green and safe, but 20% of the forest is a dry, burning inferno. If you try to water the whole forest, you run out of water before you stop the fire. But if you focus only on the burning patch, you can save the whole forest.

2. The "Targeting" Dilemma (Who gets the water?)

The team tested two ways to decide who gets the medicine:

• Method A: The Detective (Risk Screening): You interview every person, ask them about their private habits, and try to guess who is most likely to catch HIV.
  • The Problem: This is slow, expensive, and embarrassing. It's like trying to find a needle in a haystack by asking every piece of hay, "Are you a needle?" It also stigmatizes people.
• Method B: The Weatherman (Geographic Prioritization): You look at the map. If a town has a history of "fires" (high infection rates), you just offer the medicine to everyone in a specific group (like young women) in that town. You let them decide if they want the shield.
  • The Result: The paper found that Method B works just as well as Method A, but it's faster, cheaper, and less judgmental. It turns out that in high-fire towns, the people who actually need the shield are the ones who will pick it up when offered.

3. The "Price Tag" (How much is too much?)

The medicine is currently expensive. The researchers calculated the "break-even point."

• The High-Price Scenario ($125/year): If the medicine costs $125 a year, you can only afford to use it in the worst-fire zones (like parts of South Africa, Mozambique, and Lesotho). In these places, giving it to young women (ages 15–24) is a great deal because it stops so many infections.
• The Low-Price Scenario ($55/year): If the price drops to $55, the "affordable zone" expands. Suddenly, you can afford to offer it to more towns and more people, saving even more lives.

4. The "Magic Number" (Young Women in Hotspots)

The study found a "sweet spot" for maximum impact.

• The Strategy: Go to the towns with the highest fire rates. Offer the injection to young women aged 15–24.
• The Magic: In South Africa, if you do this, you only need to cover about 4% of the total adult population to stop about 18–20% of all new infections.
• The Analogy: It's like putting a single, strategic firebreak around a burning house. You don't need to build a wall around the whole city; you just need to protect the specific house that is burning the hottest, and the fire stops spreading.

5. The "Sensitivity" (What if things change?)

The researchers also asked, "What if we are wrong about how much HIV hurts a person's life?" or "What if the medicine is slightly less effective?"

• The Result: Even if they made their assumptions more conservative (pessimistic), the strategy still worked. The "high-fire" towns were still the best places to spend the money. The map didn't change; only the size of the "affordable zone" shifted slightly.

The Bottom Line

You don't need to be a detective to stop this virus. You just need a good map.

If you have limited money, don't try to treat everyone everywhere. Instead, find the towns where the virus is spreading fastest, and offer this long-acting medicine to young women in those specific towns. It's a "sniper" approach rather than a "shotgun" approach.

• If the price is high: Only hit the hottest spots.
• If the price drops: You can hit more spots.
• The Goal: Stop the fire with the least amount of water possible, saving the most lives for the least cost.

This paper gives health leaders a clear, simple rule: Look at the map, find the hotspots, and aim your resources there.

Technical Summary

1. Problem Statement

Long-acting injectable HIV pre-exposure prophylaxis (LA-PrEP), specifically Lenacapavir, offers a transformative opportunity to reduce HIV incidence in Eastern and Southern Africa (ESA). However, its implementation faces two critical constraints:

• High Costs: The product and delivery costs are significant, and health budgets in ESA are increasingly constrained.
• Prioritization Dilemma: Traditional risk-prioritization strategies rely on individual-level behavioral screening to identify high-risk individuals. These tools often have mixed performance, miss key populations (particularly young women), add operational complexity/costs, and can induce stigma. Conversely, universal provision in low-incidence areas is inefficient and potentially cost-prohibitive.

The central question is: How can Lenacapavir be delivered to maximize health impact and cost-effectiveness without relying on complex, stigmatizing individual risk screening?

2. Methodology

The authors developed a heuristic, static mathematical model to estimate the direct health and economic impact of Lenacapavir delivery across 837 districts in 11 high-burden ESA countries. Unlike complex dynamic transmission models, this approach uses simple formulas based on district-level incidence data.

Key Model Components:

• Data Inputs: District-level HIV incidence, prevalence, and population at risk were derived from the Naomi model (UNAIDS 2025 estimates), synthesized from population-based surveys and routine service data.
• Intervention Parameters:
  • Efficacy: Assumed at 95% for 6 months (based on Phase III trials).
  • Costs: Modeled at two fully loaded annual costs per person per year (pppy): $125 (base case, including drugs, testing, personnel, demand generation) and $55 (optimistic scenario with reduced commodity pricing).
  • Health Economics: Cost-effectiveness was assessed against a threshold of $500 per Disability-Adjusted Life Year (DALY) averted. Assumptions included $5,000 discounted lifetime HIV treatment costs and 10 DALYs lost per infection.
• Risk Heterogeneity Assumption:
  • The model assumes a Gamma distribution (shape parameter = 1) for risk within districts.
  • Crucially, it tests a "Universal Offer with Self-Selection" scenario: If PrEP is offered universally to a demographic group (e.g., women 15–24), it assumes uptake occurs primarily among those with >2x the district-level average risk. This aligns with empirical data from the ECHO trial showing self-selected users have significantly higher risk than non-users.
• Scenarios: The study compared universal offers in high-incidence districts against stratified risk approaches, analyzing outcomes by geography, age, and sex.

3. Key Contributions

• Geographic Granularity: The study moves beyond country-level averages to analyze district-level heterogeneity, revealing that 50% of new infections occur in districts containing less than 20% of the at-risk adult population.
• Alternative to Behavioral Screening: It provides evidence that geographic prioritization combined with a universal offer to specific demographics (e.g., young women) can achieve efficiency comparable to complex behavioral risk-targeting, without the operational burden or stigma of individual screening.
• Price Threshold Analysis: The model establishes specific price thresholds for cost-effectiveness based on local incidence rates, offering actionable guidance for procurement and pricing negotiations.
• Simplicity and Transparency: The authors demonstrate that a simple, transparent heuristic model can yield policy conclusions consistent with complex dynamic transmission models, making it more accessible for decision-makers.

4. Key Results

• Geographic Concentration: High-incidence districts (≥5 infections/1,000 person-years) are concentrated in South Africa, Mozambique, Lesotho, and eSwatini. These districts account for 34.1% of new infections but contain only 11% of the at-risk population.
• Cost-Effectiveness by Incidence:
  • In high-incidence districts (South Africa, Mozambique, Lesotho, eSwatini), Lenacapavir is cost-effective at $50–$100 pppy.
  • In low-incidence districts, the Number Needed to Treat (NNT) exceeds 1,000, and costs per DALY averted often exceed acceptable thresholds.
• South Africa Case Study (52 Districts):
  • Target Group: Women aged 15–24.
  • Scenario: Universal offer assuming uptake by those with >2x district average risk.
  • At $55 pppy: Cost-effective in all 52 districts. This strategy covers only 4.1% of the HIV-negative adult population (15–49) but reaches 18.2% of all new infections.
  • At $125 pppy: Cost-effective in 45 of 52 districts.
  • Efficiency: Achieving 25% of new infections required covering only 5.5% of the population under the high-risk uptake assumption, compared to 11% under an average-risk assumption.
• Comparison to Dynamic Models: The results (approx. 20% incidence reduction with 3–5% coverage) align closely with complex agent-based models that prioritize discrete key populations (e.g., sex workers, MSM), suggesting the geographic/universal approach is a viable, less complex alternative.
• Sensitivity: Results were robust to variations in DALY assumptions (7.5 vs. 10) and treatment costs, though the assumption of high-risk self-selection (>2x risk) remained the single largest determinant of efficiency.

5. Significance and Implications

• Policy Guidance: The paper provides a practical framework for phased implementation. Decision-makers can prioritize Lenacapavir rollout in high-incidence districts first, focusing on young women, to maximize impact per dollar spent.
• Operational Feasibility: By advocating for "universal offer" in high-risk geographies rather than individual screening, the strategy reduces stigma, simplifies logistics, and empowers individuals to self-select based on perceived risk.
• Economic Viability: The findings suggest that if Lenacapavir costs can be driven down to $55 pppy, it becomes a cost-saving or highly cost-effective intervention across almost all high-burden districts in South Africa, even without granular risk stratification.
• Future Research: The study highlights the need for implementation science to quantify real-world uptake patterns among those offered universal PrEP to validate the "self-selection" assumption.

In conclusion, the paper argues that geographically prioritized, universal delivery of Lenacapavir to young women in high-incidence districts is a highly efficient, cost-effective, and operationally feasible strategy to accelerate HIV incidence declines in Eastern and Southern Africa.